{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:22:58Z","timestamp":1791087778915,"version":"4.1.0"},"reference-count":25,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Limited treatment options are available for implant-associated infections caused by methicillin (meticillin)-resistant\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            (MRSA). We compared the activity of daptomycin (alone and with rifampin [rifampicin]) with the activities of other antimicrobial regimens against MRSA ATCC 43300 in the guinea pig foreign-body infection model. The daptomycin MIC and the minimum bactericidal concentration in logarithmic phase and stationary growth phase of MRSA were 0.625, 0.625, and 20 \u03bcg\/ml, respectively. In time-kill studies, daptomycin showed rapid and concentration-dependent killing of MRSA in stationary growth phase. At concentrations above 20 \u03bcg\/ml, daptomycin reduced the counts by &gt;3 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml in 2 to 4 h. In sterile cage fluid, daptomycin peak concentrations of 23.1, 46.3, and 53.7 \u03bcg\/ml were reached 4 to 6 h after the administration of single intraperitoneal doses of 20, 30, and 40 mg\/kg of body weight, respectively. In treatment studies, daptomycin alone reduced the planktonic MRSA counts by 0.3 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml, whereas in combination with rifampin, a reduction in the counts of &gt;6 log\n            <jats:sub>10<\/jats:sub>\n            CFU\/ml was observed. Vancomycin and daptomycin (at both doses) were unable to cure any cage-associated infection when they were given as monotherapy, whereas rifampin alone cured the infections in 33% of the cages. In combination with rifampin, daptomycin showed cure rates of 25% (at 20 mg\/kg) and 67% (at 30 mg\/kg), vancomycin showed a cure rate of 8%, linezolid showed a cure rate of 0%, and levofloxacin showed a cure rate of 58%. In addition, daptomycin at a high dose (30 mg\/kg) completely prevented the emergence of rifampin resistance in planktonic and adherent MRSA cells. Daptomycin at a high dose, corresponding to 6 mg\/kg in humans, in combination with rifampin showed the highest activity against planktonic and adherent MRSA. Daptomycin plus rifampin is a promising treatment option for implant-associated MRSA infections.\n          <\/jats:p>","DOI":"10.1128\/aac.00047-09","type":"journal-article","created":{"date-parts":[[2009,4,14]],"date-time":"2009-04-14T00:33:44Z","timestamp":1239669224000},"page":"2719-2724","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":169,"title":["Efficacy of Daptomycin in Implant-Associated Infection Due to Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>\n            : Importance of Combination with Rifampin"],"prefix":"10.1128","volume":"53","author":[{"given":"Anne-Kathrin","family":"John","sequence":"first","affiliation":[{"name":"Infectious Diseases, Department of Biomedicine, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Baldoni","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Biomedicine, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Haschke","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology and Toxicology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Rentsch","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Schaerli","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Transplantation and Immunology, Novartis Pharma Schweiz AG, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Zimmerli","sequence":"additional","affiliation":[{"name":"Basel University Medical Clinic, Kantonsspital, Liestal, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Trampuz","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Department of Biomedicine, University Hospital Basel, Basel, Switzerland"},{"name":"Division of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/20.2.213"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-06"},{"key":"e_1_3_2_4_2","unstructured":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2006"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/39.2.235"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1318-1323.2003"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2004.11.010"},{"key":"e_1_3_2_8_2","first-page":"222","volume":"32","year":"2004","unstructured":"Giulieri, S. G., P. Graber, P. E. Ochsner, and W. Zimmerli. 2004. Management of infection associated with total hip arthroplasty according to a treatment algorithm. Infection32:222-228.","journal-title":"Infection"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro821"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01378.x"},{"key":"e_1_3_2_11_2","unstructured":"Manual of clinical microbiology 2003"},{"key":"e_1_3_2_12_2","unstructured":"Methods for determining bactericidal activity of antimicrobial agents 1999"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.8.805"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00350-06"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-74"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.8.2538-2544.2003"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2008.08.029"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh546"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00120-07"},{"key":"e_1_3_2_20_2","first-page":"249","volume":"87","year":"2005","unstructured":"Trebse, R., V. Pisot, and A. Trampuz. 2005. Treatment of infected retained implants. J. Bone Joint Surg. Br.87:249-256.","journal-title":"J. Bone Joint Surg. Br."},{"key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ccc.2007.12.013","volume":"24","year":"2008","unstructured":"Tverdek, F. P., C. W. Crank, and J. Segreti. 2008. Antibiotic therapy of methicillin-resistant Staphylococcus aureus in critical care. Crit. Care Clin.24:249-260, vii-viii.","journal-title":"Crit. Care Clin."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/14.6.1251"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.31-33.2002"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.5.959"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/146.4.487"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.279.19.1537"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00047-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00047-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:08:32Z","timestamp":1645474112000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00047-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":25,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["10.1128\/AAC.00047-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.00047-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7]]},"assertion":[{"value":"2009-01-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-04-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}